Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
4 hedge funds and large institutions have $38.6K invested in Reviva Pharmaceuticals Warrants in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 0.7% → 0.53% (-0.16%)
20% less funds holding
Funds holding: 5 → 4 (-1)
66% less capital invested
Capital invested by funds: $113K → $38.6K (-$74K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$935 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$17.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
Arena Investors
Purchase,
New York
| $21.3K | – | – | – |
|
2
Walleye Capital
New York
| $9.1K | – | – | – |
|
3
Walleye Trading
New York
| $6.95K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.26K | +$935 | +2,279 | +96% |
|
|
BRWA
5
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$17.1K | -11,101 | Closed |
|
RVPHW Hedge Fund Activity: Q2 2024 in Review
4 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q2 2024, worth a combined $38.6K — down 66% from $113K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RVPHW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $935. The largest seller was B. Riley Wealth Advisors, exiting entirely with an estimated $17.1K sold.
- 4 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q2 2024, down from 5 in Q1 2024.
- Funds reported $38.6K of Reviva Pharmaceuticals Warrants stock for Q2 2024, down 66% quarter-over-quarter.
- 0 funds opened new Reviva Pharmaceuticals Warrants positions in Q2 2024 and 1 closed out, a net change of -1 holder.
- The largest Reviva Pharmaceuticals Warrants buyer in Q2 2024 was UBS Group, an estimated $935 added.
- The largest Reviva Pharmaceuticals Warrants seller in Q2 2024 was B. Riley Wealth Advisors, an estimated $17.1K sold.
Based on aggregated 13F filings for Q2 2024.